

# Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis

Kjetil Bjornevik, MD, PhD, Éilis J. O'Reilly, ScD, James D. Berry, MD, Clary B. Clish, PhD, Sarah Jeanfavre, MSc, Ikuko Kato, PhD, Laurence N. Kolonel, MD, PhD, Loïc Le Marchand, MD, PhD, Marjorie L. McCullough, ScD, Sabrina Paganoni, MD, PhD, Michael A. Schwarzschild, MD, PhD, Evelyn O. Talbot, DrPH, Robert B. Wallace, MD, Zhongli Zhang, PhD, JoAnn E. Manson, MD, DrPH, and Alberto Ascherio, MD, DrPH

## Correspondence

Dr. Bjornevik  
kbjorne@hsph.harvard.edu

*Neurology*® 2019;92:e2081-e2088. doi:10.1212/WNL.0000000000006669

## Abstract

### Objective

To assess whether prediagnostic levels of plasma branched-chain amino acids (BCAAs) are associated with amyotrophic lateral sclerosis (ALS) risk.

### Methods

We included participants from 5 large cohort studies—The Nurses' Health Study, the Health Professionals Follow-up Study, the Cancer Prevention Study II Nutrition, the Multiethnic Cohort Study, and the Women's Health Initiative—and identified 275 individuals who developed ALS during follow-up. Two controls were randomly selected for each case, matched on cohort, age, sex, fasting status, and time of blood draw. We measured metabolites using liquid chromatography–mass spectrometry and used conditional logistic regression to estimate rate ratios (RRs) and 95% confidence intervals (CIs) for the association of individual BCAAs with ALS risk.

### Results

None of the 3 BCAAs was associated with a higher ALS risk. The risk estimates were similar for leucine (RR top vs bottom quartile: 0.87, 95% CI 0.57–1.33), isoleucine (RR top vs bottom quartile: 0.81, 95% CI 0.52–1.24), and valine (RR top vs bottom quartile: 0.80, 95% CI 0.52–1.23) in a multivariable analysis adjusted for body mass index, smoking, level of education, and physical activity. The estimates did not vary significantly by sex, fasting status, or time interval between blood draw and disease onset.

### Conclusion

The results from this study do not support the hypothesis that BCAAs are risk factors for ALS.

From the Departments of Nutrition (K.B., É.J.O., Z.Z., A.A.) and Epidemiology (J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital (S.P.), Boston; Metabolomics Platform (C.B.C., S.J.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Epidemiology Research Program (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital, Charlestown; Harvard Medical School (S.P., M.A.S.), Boston, MA; Department of Epidemiology (E.O.T.), Graduate School of Public Health, University of Pittsburgh, PA; Department of Epidemiology (R.B.W.), College of Public Health, University of Iowa, Iowa City; and Department of Medicine (J.E.M.) and Channing Division of Network Medicine (A.A.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

## Glossary

**ALS** = amyotrophic lateral sclerosis; **BCAA** = branched-chain amino acids; **BMI** = body mass index; **CI** = confidence interval; **CPS-II Nutrition** = Cancer Prevention Study II Nutrition Cohort; **HPFS** = Health Professionals Follow-up Study; **ICD-9** = International Classification of Diseases, Ninth Revision; **MEC** = Multiethnic Cohort Study; **NHS** = Nurses' Health Study; **NMR** = nuclear magnetic resonance; **OR** = odds ratio; **PPV** = positive predictive value; **RR** = rate ratio; **WHI** = Women's Health Initiative.

The branched-chain amino acids (BCAAs) valine, leucine, and isoleucine play an important role in glutamate metabolism,<sup>1</sup> which has been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS).<sup>2</sup> As BCAAs have been postulated to restore impaired glutamate metabolism,<sup>3</sup> the effect of these essential amino acids on ALS progression has been explored in clinical trials. Several of these have, however, not only failed to support a beneficial role of BCAAs but provided evidence for potential adverse effects. In an Italian trial, there was an excess of deaths in the group treated with BCAAs,<sup>4</sup> and in a later US trial, the estimated decline in forced vital capacity, one of the a priori selected outcomes, was 2.5 times greater in the treatment group as compared to placebo.<sup>5</sup> As BCAAs may affect pathways relevant to ALS, including downregulation of antioxidant genes associated with familial ALS and induction of hyperexcitability in cortical neurons,<sup>6,7</sup> it has been proposed that dietary supplements containing BCAAs, which are commonly used by Italian soccer players,<sup>8</sup> could be one of the factors that contributed to their elevated ALS risk.<sup>9,10</sup>

Whether BCAAs increase the risk of ALS is currently not known. Higher levels have been reported in patients with ALS compared to controls,<sup>11,12</sup> but as the amino acids' concentrations may have been affected by the disease itself, it is unclear whether they are etiologically relevant. Prospective studies including prediagnostic samples from individuals later developing ALS could be more informative, but they are difficult to conduct due to the low incidence of the disease.

To address this, we conducted a pooled analysis of 5 large prospective cohort studies to assess whether higher prediagnostic plasma levels of BCAAs are associated with an increased ALS risk.

## Methods

### Study populations

The study population included participants from 5 large cohort studies: The Nurses' Health Study (NHS), the Health Professionals Follow-up Study (HPFS), the Cancer Prevention Study II Nutrition Cohort (CPS-II Nutrition), the Multiethnic Cohort Study (MEC), and the Women's Health Initiative (WHI). Detailed descriptions of the individual cohorts have previously been published.<sup>13–17</sup> In short, the NHS began in 1976 with 121,700 female nurses aged 30–55 years at baseline.<sup>13</sup> In 1988, all nurses were invited to provide a blood sample, which was collected from 32,826 women

during 1989 and 1990. Thirty-nine nurses who gave a blood sample developed ALS between blood draw and end of follow-up. The HPFS began in 1986 and enrolled 51,529 male health professionals aged 40–75 years at baseline.<sup>14</sup> All of the participants were invited to provide a blood sample, which was collected from 18,018 men between 1993 and 1995. Twenty-six men were identified with ALS between blood draw and end of follow-up. Every 2 years, the participants in these 2 cohorts were followed up with similar questionnaires on medical history and health-related behavior. The CPS-II Nutrition cohort was established in 1992 and consists of a subpopulation of the larger CPS-II cohort.<sup>15</sup> It includes 86,406 men and 97,788 women aged 50–74 years at baseline. These participants completed a questionnaire on lifestyle and dietary factors at baseline, in 1997 and biennially thereafter. In 1998, participants living in urban and suburban areas were invited to provide a blood sample, which was collected from 39,380 members of the cohort. Among these, 58 participants died of ALS during follow-up. The MEC cohort study began in 1993 and consists of 96,810 men and 118,441 women aged 45–75 years at baseline with the self-reported ethnic background of African American, Japanese American, Latino, Native Hawaiian, or white.<sup>16</sup> The participants completed a lifestyle and disease history questionnaire at baseline, and follow-up questionnaires every 5 years thereafter. A total of 67,594 members of the cohort provided a blood sample, which was largely collected between 2001 and 2006. Thirty-one participants died of ALS between blood draw and end of follow-up. The WHI study recruited a total of 161,809 postmenopausal women aged 50–79 years between 1993 and 1998, who were enrolled into one or more of 3 clinical trials ( $n = 68,133$ ) or into the observational study ( $n = 93,676$ ).<sup>17</sup> At baseline, all of the participants completed a questionnaire on lifestyle and disease history and provided a blood sample. A total of 121 participants died of ALS after blood draw until end of follow-up. End of follow-up was December 31, 2010, for NHS, HPFS, and CPS-II Nutrition; September 30, 2012, for WHI; and December 31, 2012, for MEC.

### Standard protocol approvals, registrations, and patient consents

All of the studies included were reviewed and approved by the institutional review board at the institution where each study was conducted.

### Endpoint definition

In the CPS-II Nutrition, MEC, and WHI studies, we identified ALS cases through a search of the National Death Index. WHI

also compiled self-reported ALS information for women in the observational study, but it was never adjudicated. All individuals with ICD-9 code 335.2 (motor neuron disease) listed as the underlying or contributing cause of death were considered to have had ALS. In a previous validation study, ALS was the primary diagnosis in 90% of the individuals for whom code 335.2 was listed as the cause or contributory cause of death.<sup>18</sup> We assigned the date of onset to 3 years before the date of death, based on median survival among patients with ALS.<sup>19</sup>

In the NHS and HFPS, we identified incident ALS by self-report on the biennial questionnaire. For participants reporting a diagnosis of ALS, we requested permission to contact the treating neurologist and obtain a copy of the medical records. Due to the progressive nature of ALS, many of the patients had already died before we could obtain permission to release the medical records. For these patients, we sent the request to the closest family member. We asked the treating neurologist to complete a questionnaire, which was based on the revised El Escorial criteria, on the certainty of the diagnosis (definite, probable, or possible), and the clinical history. The final confirmation of the diagnosis was made after reviewing medical records by a neurologist with experience in ALS diagnosis. We observed few discrepancies between the diagnosis made by the field neurologist and the neurologist with expertise in ALS, and the differences were mostly limited to whether patients were diagnosed with definite or probable ALS. Patients defined as definite or probable cases were included in the study. If we were unable to obtain a copy of the medical record or the neurologist's questionnaire to confirm the diagnosis of self-reported ALS, only the patients with ALS specifically listed on the death certificate were included.

For each ALS case, we randomly selected 2 controls who were alive at the time of the case diagnosis and matched on cohort, birth year ( $\pm 1$  year), sex, ethnicity, fasting status, and time of blood draw. For one of the cases, only one matched control was included in the final analyses, as the assessment of metabolites failed in the other matched control.

### Assessment of metabolites

Across the cohorts, blood samples were collected from a total of 319,627 participants and were stored at  $-70^{\circ}\text{C}$  or below. For the individuals who developed ALS and their matched controls, 10  $\mu\text{L}$  of plasma from each individual was used for the metabolomics analysis. Triplets of plasma samples (one case with its 2 matched controls) were handled identically and assayed in the same analytic run. The order of the plasma samples within each case-control triplet was arranged at random, to ensure that all assays were conducted without knowledge of the case/control status. We profiled the metabolites using hydrophilic interaction liquid chromatography coupled to positive ion mode mass spectrometry at the Broad Institute (Boston, MA), as previously described.<sup>20</sup>

### Assessment of covariates

Information on other covariates of interest, including smoking status, height, weight, educational level, physical activity, and diabetes status, was collected at baseline for all cohorts, and every 2 years since baseline in HPFS and NHS. Participants self-reported a diagnosis of type 1 or type 2 diabetes mellitus. These specific covariates were included in multivariable models, as they have previously been associated with ALS risk, and could be potential confounders. The nearest covariate data collected before or at the time of blood draw were used.

### Statistical analysis

To account for the matched study design, we used conditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association of BCAAs with ALS risk. As controls in our study were selected using risk-set sampling, the ORs estimate incidence rate ratios (IRRs).<sup>21</sup> We log-transformed and standardized the amino acids within cohort and sex to account for possible differences that may have been introduced as cohort samples were processed at different times. We estimated the correlation between log-transformed levels of individual BCAAs, glutamate, urate, and body mass index (BMI) using Pearson correlation, and tested whether the BCAAs were significantly different among diabetic and nondiabetic participants using a 2-sided *t* test. The amino acids were modeled as both continuous (per 1 SD increase) and categorical variables to maximize power and to explore possible nonlinear relationships. For the categorical analyses, we categorized the participants into cohort and sex-specific quartiles based on the distribution among the controls. We tested for a linear trend across the quartiles by assigning the median value to each quartile and modeled this as a continuous variable. Multivariable models were used to assess the influence of possible confounders, including BMI (using weight reported closest to time of blood draw, continuous), educational level ( $<$  high school, high school,  $>$  high school), smoking status (never smoker, past smoker, current smoker), and physical activity (approximate tertiles corresponding to low, medium, and high activity levels). We categorized participants according to tertiles of metabolic equivalent hours of total physical activity in NHS, HPFS, and WHI, while the amount of moderate and vigorous physical activity was used for CPS-II and MEC. When data were missing for a covariate, we used a missing indicator (6.7% of the participants had 1 or more missing covariate data). We tested for effect modification by sex, fasting status ( $< 4$  vs  $\geq 4$  hours since last meal), and time from blood collection to disease onset ( $< 5$  vs  $\geq 5$  years) by including a product term of individual BCAAs and the modifier in separate models. We conducted a sensitivity analysis excluding individuals with diabetes, as diabetes has been associated with marked alterations in the metabolome,<sup>22</sup> including elevated BCAA levels,<sup>23</sup> and has also been associated with the risk of ALS.<sup>24</sup> All of the analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC). The  $\alpha$ -level was set at 0.05.

## Data availability

The datasets analyzed in the current study are not publicly available because of restricted access, but further information about the datasets is available from the corresponding author on reasonable request.

## Results

We identified a total of 275 individuals who developed ALS among the 319,627 participants who provided blood samples in these 5 cohort studies. There was a higher proportion of female compared to male participants in our study. The cases were slightly more likely to have ever smoked compared to controls and had slightly lower BMI at baseline (table 1). Further, fewer cases had higher educational level than high school compared to the controls. The other characteristics were similarly distributed. Plasma levels of leucine, isoleucine, and valine correlated significantly with each other, and higher levels correlated with higher BMI (table 2). Further, higher levels of the amino acids correlated significantly with higher levels of glutamate and with urate. The levels of all 3 BCAAs were higher among diabetic compared to nondiabetic participants ( $p = 0.006$ ,  $p = 0.004$ , and  $p < 0.001$  by the  $t$  test for leucine, isoleucine, and valine, respectively).

Higher levels of valine were associated with a lower ALS risk in analyses adjusted for age, sex, and matching variables, but the trend was not monotonic and was no longer statistically significant after further adjustment for BMI. Other BCAAs were not significantly associated with ALS risk, neither in the continuous nor in the categorical analyses (table 3). Adjustment for BMI, smoking, physical activity, and educational level did not materially alter the results. Total BCAA plasma level was not associated with ALS risk (data not shown).

None of the 3 metabolites was significantly associated with ALS risk in any of the predefined subgroup analyses (table 4). The RR estimates were slightly lower in women compared to men, but the difference was not significant. Similarly, the estimates were lower among those with fasting samples compared to those with nonfasting samples, but the estimates were not statistically significantly different. The estimates from analyses restricted to those with longer interval ( $\geq 5$  years) between blood draw and ALS onset were similar to those restricted to those with shorter interval ( $< 5$  years). The results were similar when we restricted the analyses to individuals with an interval of 2 years or less between blood draw and ALS onset (data not shown).

In a sensitivity analysis, we excluded participants who had developed diabetes before the blood draw, as insulin resistance has been associated with increased BCAA levels and diabetes has been suggested to affect ALS risk.<sup>23,24</sup> However, none of the 3 BCAAs was associated with ALS risk when excluding patients with diabetes ( $n = 49$ ). In a multivariable model adjusting for age, sex, BMI, smoking, physical activity,

and educational level, the RR for ALS per 1 SD increase in amino acid levels was 0.88 (95% CI 0.76–1.03) for leucine, 0.92 (95% CI 0.78–1.08) for isoleucine, and 0.87 (95% CI 0.75–1.02) for valine.

## Discussion

In this pooled analysis of 5 large cohort studies, we did not find any association between prediagnostic plasma levels of BCAAs and the risk of ALS. The results did not vary significantly with time to ALS onset and were not materially changed when we adjusted for the most relevant confounders. Our findings do not support the hypothesis that plasma BCAAs are risk factors for ALS.

Previous research on BCAAs and ALS risk is sparse, and no study has previously evaluated the association between prediagnostic plasma levels and disease risk. Some,<sup>11,12,25</sup> but not all,<sup>26,27</sup> studies comparing the metabolome in patients with ALS with controls reported alterations in the metabolism of BCAAs in patients. In a study comparing the metabolome in 22 patients with ALS with 28 controls with other neurologic conditions, the plasma levels of all 3 BCAAs were higher in patients with ALS compared to controls in analyses using nuclear magnetic resonance (NMR) spectroscopy.<sup>11</sup> The results were similar in a study comparing the metabolome in the same cohort of patients and controls using mass spectrometry, but only plasma levels of valine and isoleucine were significantly increased in patients with ALS.<sup>12</sup> Further, one study used NMR to try to identify a diagnostic profile discriminating 95 patients with motor neuron disease from 86 patients with other neurologic diseases and reported that valine and isoleucine measured in the CSF were among the metabolites contributing most to the final diagnostic model.<sup>25</sup> In our study, we did not find any differences in prediagnostic BCAA levels in those later developing ALS compared to their matched controls, which indicates that the amino acids do not contribute to the earliest etiologic events. Still, it is possible that these amino acids affect disease processes at a later stage, which could be consistent with the results from previous metabolomics studies, the possible adverse effects reported in clinical trials,<sup>4,5</sup> and the findings from in vivo and in vitro studies suggesting that BCAAs affect pathways relevant to the disease.<sup>6,7</sup>

BCAAs contribute both to de novo synthesis and buffering of glutamate, which in excessive amounts may contribute to excitotoxicity in ALS. The amino acids, in particular leucine, rapidly cross into the CNS,<sup>28</sup> and provide approximately 25% of the amino groups of brain glutamate.<sup>29</sup> It has been suggested that high levels of BCAAs lead to an excess of glutamate, which could trigger motor neuron death due to excessive stimulation of glutamate receptors.<sup>30</sup> This is supported by evidence from an animal study where a diet enriched in BCAAs induced a hyperexcitability of motor neurons, which was related to a specific glutamate receptor (NMDA receptor), as the effect was abolished after



**Table 1** Selected age-standardized characteristics

Characteristics	Cases (n = 275)	Controls (n = 549)	p Value
<b>Age, y<sup>a</sup></b>			
Mean (SD)	64.6 (7.2)	64.6 (7.2)	—
<b>Sex, n (%)<sup>a</sup></b>			
Male	75 (27.3)	150 (27.3)	—
Female	200 (72.7)	399 (72.7)	
<b>Fasting status, h, n (%)<sup>a</sup></b>			
<4	73 (26.6)	155 (28.2)	—
≥4	202 (73.5)	394 (71.8)	
<b>Interval from blood draw to ALS onset, y<sup>a</sup></b>			
Median (IQR)	4.8 (1.9–7.8)	—	—
<5, n (%)	144 (52.4)	—	—
≥5, n (%)	131 (47.6)	—	—
<b>Body mass index</b>			
Mean (SD)	26.2 (4.4)	26.9 (5.2)	0.034
<b>Smoking status, n (%)<sup>a</sup></b>			
Never smoker	123 (44.7)	264 (48.1)	0.82
Past smoker	128 (46.6)	239 (43.5)	
Current smoker	18 (6.6)	36 (6.6)	
Unknown	6 (2.2)	10 (1.8)	
<b>Ethnicity, n (%)<sup>a</sup></b>			
White	225 (81.8)	448 (81.6)	0.98
African American	21 (7.6)	39 (7.1)	
Hispanic	8 (2.9)	17 (3.1)	
Asian	10 (3.6)	20 (3.6)	
Other	6 (2.2)	17 (3.1)	
Not reported	5 (1.8)	8 (1.5)	
<b>Education, n (%)<sup>a</sup></b>			
< High school	13 (4.8)	20 (3.7)	0.50
High school	48 (17.7)	84 (15.4)	
> High school	211 (77.6)	442 (81.0)	
<b>Physical activity, n (%)<sup>a</sup></b>			
Low levels	87 (32.8)	175 (33.0)	0.99
Medium level	79 (29.8)	157 (29.6)	
High level	99 (37.4)	199 (37.5)	
<b>Diabetes, n (%)</b>			
Yes	14 (5.1)	35 (6.4)	0.46
No	261 (94.9)	514 (93.6)	

Abbreviation: IQR = interquartile range.

Values are standardized to the age distribution of the study population. Values of polytomous variables may not sum up to 100% due to rounding. p Values are not given for matching factors (age, sex, and fasting status), as these are similar in the 2 groups by design.

<sup>a</sup> Value is not age-adjusted.

**Table 2** Pearson correlation coefficients for individual branched-chain amino acids, urate, and body mass index (BMI)

	Leucine	Isoleucine	Valine	Glutamate	Urate
Isoleucine	0.936 <sup>a</sup>				
Valine	0.894 <sup>a</sup>	0.862 <sup>a</sup>			
Glutamate	0.333 <sup>a</sup>	0.317 <sup>a</sup>	0.319 <sup>a</sup>		
Urate	0.158 <sup>a</sup>	0.169 <sup>a</sup>	0.188 <sup>a</sup>	0.197 <sup>a</sup>	
BMI	0.206 <sup>a</sup>	0.224 <sup>a</sup>	0.272 <sup>a</sup>	0.227 <sup>a</sup>	0.302 <sup>a</sup>

<sup>a</sup>  $p < 0.001$  (2-tailed).

administration of a specific NMDA channel blocker.<sup>31</sup> However, BCAAs also serve as a buffering mechanism against excessive glutamate levels. After BCAAs are metabolized in astrocytes, their ketoacids are released into the extracellular fluid and can subsequently be taken up by neurons.<sup>1</sup> Ketoleucine can be converted back to leucine in a process that consumes glutamate, which provides a mechanism for preventing excessive amounts of the amino acid.<sup>1</sup> It is thus unclear whether higher BCAA intake in humans would lead to levels of glutamate that could have neurotoxic effects.

Our study has several strengths. First, the nested case-control study design, where the participants were drawn from existing cohort studies, minimizes the risk of selection bias when choosing the controls. Second, the prospective study design with samples collected years before disease onset limits the risk of reverse causation bias. Finally, we were able to account for several possible confounders suggested to be relevant in ALS, including BMI, physical activity, smoking, and diabetes.

Our study also has some limitations. While we drew participants from 5 large cohort studies, we were able to identify

**Table 3** Rate ratio (RR) for amyotrophic lateral sclerosis according to prediagnostic branched amino acid plasma levels

Incident cases (275 cases, 549 noncases)	RR (95% CI)		
	Leucine	Isoleucine	Valine
<b>Model 1<sup>a</sup></b>			
Per SD	0.88 (0.76–1.02)	0.90 (0.78–1.04)	0.86 (0.75–0.99)
<b>Across quartiles</b>			
Q1	1 (reference)	1 (reference)	1 (reference)
Q2	0.81 (0.54–1.23)	0.77 (0.51–1.15)	0.78 (0.52–1.16)
Q3	0.67 (0.44–1.01)	0.72 (0.48–1.07)	0.51 (0.33–0.78)
Q4	0.81 (0.54–1.23)	0.74 (0.49–1.11)	0.72 (0.48–1.09)
<i>p</i> For trend	0.23	0.13	0.046
<b>Model 2<sup>b</sup></b>			
Per SD	0.90 (0.78–1.05)	0.93 (0.80–1.09)	0.89 (0.77–1.04)
<b>Across quartiles</b>			
Q1	1 (reference)	1 (reference)	1 (reference)
Q2	0.85 (0.56–1.29)	0.80 (0.53–1.21)	0.80 (0.53–1.20)
Q3	0.72 (0.47–1.09)	0.77 (0.51–1.16)	0.54 (0.35–0.83)
Q4	0.87 (0.57–1.33)	0.81 (0.52–1.24)	0.80 (0.52–1.23)
<i>p</i> For trend	0.40	0.29	0.14

Abbreviation: CI = confidence interval.

<sup>a</sup> Model 1: adjusted for age, sex, and matching variables.

<sup>b</sup> Model 2: additional adjustment for body mass index, smoking, level of education, and physical activity.

**Table 4** Rate ratio (RR) for amyotrophic lateral sclerosis (ALS) according to prediagnostic branched amino acid plasma levels in specific subgroups

Subgroup	RR per 1 SD increase (95% CI) <sup>a</sup>		
	Leucine	Isoleucine	Valine
<b>Sex</b>			
Female	0.87 (0.72–1.04)	0.87 (0.72–1.05)	0.87 (0.73–1.05)
Male	0.96 (0.72–1.28)	1.04 (0.78–1.38)	0.92 (0.67–1.25)
<b>p For interaction</b>	0.35	0.15	0.64
<b>Fasting status, h</b>			
<4	1.15 (0.82–1.59)	1.12 (0.80–1.56)	1.14 (0.83–1.57)
≥4	0.83 (0.69–1.01)	0.88 (0.72–1.07)	0.85 (0.70–1.03)
<b>p For interaction</b>	0.10	0.23	0.14
<b>Interval between blood draw and ALS onset, y</b>			
<5	0.92 (0.75–1.13)	1.01 (0.81–1.25)	0.83 (0.67–1.04)
≥5	0.87 (0.70–1.09)	0.86 (0.69–1.08)	0.93 (0.75–1.16)
<b>p For interaction</b>	0.69	0.28	0.61

Abbreviation: CI = confidence interval.

<sup>a</sup> Adjusted for age, sex, body mass index, smoking, level of education, physical activity, and matching factors.

only 275 individuals who later developed ALS, due to the low incidence of the disease. This may have affected the statistical power to detect significant differences, especially in subgroup analyses. Still, given that risk estimates for all of the BCAAs with ALS risk were below 1.0, it seems unlikely that the amino acids would be associated with an increased risk if a higher number of participants had been included. Our study population only included 27% male participants, which represents an atypical ALS population, as the incidence rate of the disease is higher in men compared to women.<sup>32</sup> The unusual distribution is mainly due to the inclusion of participants from WHI, who are all female and all contributed with blood samples. We did not observe any significant differences in the results in men and women, and it is therefore unlikely that this has affected our results. We did not have information on clinical covariates, such as subtypes of ALS, and could therefore not evaluate whether there were differences between those developing familial ALS to those with sporadic ALS. Further, due to lack of clinical information, we used information from death certificates to capture ALS cases in CPS-IIN, MEC, and WHI. This may have led to misclassification of ALS in some participants, as death certificates are likely to be less accurate than medical records. In a US study, the sensitivity and positive predictive value (PPV) for use of death certificates for ALS were estimated to be 85% and 65%,<sup>33</sup> while a recent study from Denmark reported a sensitivity of 84% and an overall PPV of 82%.<sup>34</sup> Overall, this suggests that use of death certificates is an adequate, but not ideal, tool to capture patients with ALS in epidemiologic studies. We assessed the association using a single plasma

measurement per individual, which may not reflect long-term exposure of the amino acids over time. However, in a validation study in NHS and HPFS, the 3 amino acids had Spearman correlations above 0.60 when comparing 2 samples collected in the same individuals 0.8–2.3 years apart, indicating that a single measurement may reasonably reflect longer-term levels.<sup>35</sup> As data on physical activity were collected at different ages and with different methodologies across the cohorts, we may not have been able to fully adjust for this in the analyses. Finally, as is inherent to any observational study, we cannot exclude the possibility that the results may be affected by residual or unmeasured confounding that we cannot account for.

In a pooled analysis of 5 cohort studies, we did not find any significant association between prediagnostic plasma levels of BCAAs and ALS risk. Our findings suggest that high physiologic levels of these amino acids do not increase the risk of the disease.

### Author contributions

Dr. Bjornevik: drafting/revising the manuscript for content, analysis or interpretation of data, statistical analysis. Dr. O'Reilly: drafting/revising the manuscript for content, analysis or interpretation of data. Dr. Berry: drafting/revising the manuscript for content, analysis or interpretation of data. Dr. Clish: drafting/revising the manuscript for content, analysis or interpretation of data. S. Jeanfavre: drafting/revising the manuscript for content, analysis or interpretation of data. Dr. Kato: drafting/revising the manuscript for content,

acquisition of data. Dr. Kolonel: drafting/ revising the manuscript for content, acquisition of data. Dr. Le Marchand: drafting/ revising the manuscript for content, acquisition of data. Dr. McCullough: drafting/ revising the manuscript for content, acquisition of data. Dr. Paganoni: drafting/ revising the manuscript for content, analysis or interpretation of data. Dr. Schwarzschild: drafting/ revising the manuscript for content, analysis or interpretation of data. Dr. Talbott: drafting/ revising the manuscript for content, acquisition of data. Robert B. Wallace: drafting/ revising the manuscript for content, acquisition of data. Dr. Zhang: drafting/ revising the manuscript for content, analysis or interpretation of data. Dr. Manson: drafting/ revising the manuscript for content, acquisition of data. Dr. Ascherio: study concept or design, drafting/ revising the manuscript for content, analysis or interpretation of data, acquisition of data, obtaining funding. Drs. Bjornevik and Ascherio had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

## Acknowledgment

The authors acknowledge the cohorts' participants and Leslie Unger for administrative support.

## Study funding

This work was supported by a grant from the National Institute of Neurologic Diseases and Stroke (R01 NS045893) awarded to Alberto Ascherio. The NHS is funded by the NIH through grants UM1 CA186107 and R01 CA49449. The HPFS cohort is funded by the NIH through grant UM1 CA167552. The American Cancer Society funds the creation, maintenance, and updating of the CPS-II cohorts. The MEC cohort is funded by the NIH through U01 CA164973. The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, US Department of Health and Human Services, through contracts HHSN268201600018C, HHSN268201600001C, and HHSN268201600002C. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.

## Disclosure

The authors report no disclosures relevant to the manuscript. Go to [Neurology.org/N](http://Neurology.org/N) for full disclosures.

## Publication history

Received by *Neurology* April 6, 2018. Accepted in final form September 17, 2018.

## References

1. Yudkoff M, Daikhin Y, Nissim I, et al. Brain amino acid requirements and toxicity: the example of leucine. *J Nutr* 2005;135:1531S–1538S.
2. Plaitakis A. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: a hypothesis. *Ann Neurol* 1990;28:3–8.
3. Plaitakis A, Smith J, Mandeli J, Yahr MD. Pilot trial of branched-chain amino acids in amyotrophic lateral sclerosis. *Lancet* 1988;1:1015–1018.
4. The Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? *Neurology* 1993;43:2466–2470.

5. Tandan R, Bromberg MB, Forshe D, et al. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I: clinical, functional, and maximum isometric torque data. *Neurology* 1996;47:1220–1226.
6. Piscopo P, Crestini A, Adduci A, et al. Altered oxidative stress profile in the cortex of mice fed an enriched branched-chain amino acids diet: possible link with amyotrophic lateral sclerosis? *J Neurosci Res* 2011;89:1276–1283.
7. Carunchio I, Curcio L, Pieri M, et al. Increased levels of p70S6 phosphorylation in the G93A mouse model of amyotrophic lateral sclerosis and in valine-exposed cortical neurons in culture. *Exp Neurol* 2010;226:218–230.
8. Taioli E. Use of permitted drugs in Italian professional soccer players. *Br J Sports Med* 2007;41:439–441.
9. Chio A, Benzi G, Dossena M, Mutani R, Mora G. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. *Brain* 2005;128:472–476.
10. Chio A, Calvo A, Dossena M, Ghiglione P, Mutani R, Mora G. ALS in Italian professional soccer players: the risk is still present and could be soccer-specific. *Amyotroph Lateral Scler* 2009;10:205–209.
11. Wu JF, Wuolikainen A, Trupp M, et al. NMR analysis of the CSF and plasma metabolome of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects. *Metabolomics* 2016;12.
12. Wuolikainen A, Jonsson P, Ahnlund M, et al. Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson's disease and control subjects. *Mol Biosyst* 2016;12:1287–1298.
13. Bao Y, Bertoia ML, Lenart EB, et al. Origin, methods, and evolution of the three nurses' health studies. *Am J Public Health* 2016;106:1573–1581.
14. Rimm EB, Giovannucci EL, Willett WC, et al. Prospective study of alcohol consumption and risk of coronary disease in men. *Lancet* 1991;338:464–468.
15. Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society Cancer Prevention Study II Nutrition cohort: rationale, study design, and baseline characteristics. *Cancer* 2002;94:2490–2501.
16. Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. *Am J Epidemiol* 2000;151:346–357.
17. Anderson GL, Manson J, Wallace R, et al. Implementation of the women's health initiative study design. *Ann Epidemiol* 2003;13:S5–S17.
18. Weisskopf MG, McCullough ML, Calle EE, Thun MJ, Cudkovic M, Ascherio A. Prospective study of cigarette smoking and amyotrophic lateral sclerosis. *Am J Epidemiol* 2004;160:26–33.
19. Traxinger K, Kelly C, Johnson BA, Lyles RH, Glass JD. Prognosis and epidemiology of amyotrophic lateral sclerosis: analysis of a clinic population, 1997–2011. *Neuro Clin Pract* 2013;3:313–320.
20. Paynter NP, Balasubramanian R, Giulianini F, et al. Metabolic predictors of incident coronary heart disease in women. *Circulation* 2018;137:841–853.
21. Knol MJ, Vandenbroucke JP, Scott P, Egger M. What do case-control studies estimate? Survey of methods and assumptions in published case-control research. *Am J Epidemiol* 2008;168:1073–1081.
22. Guasch-Ferre M, Hruby A, Toledo E, et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. *Diabetes Care* 2016;39:833–846.
23. Mahendran Y, Jonsson A, Have CT, et al. Genetic evidence of a causal effect of insulin resistance on branched-chain amino acid levels. *Diabetologia* 2017;60:873–878.
24. Kioumourtoglou MA, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. *JAMA Neurol* 2015;72:905–911.
25. Blasco H, Nadal-Desbarats L, Pradat PF, et al. Untargeted 1H-NMR metabolomics in CSF: toward a diagnostic biomarker for motor neuron disease. *Neurology* 2014;82:1167–1174.
26. Lawton KA, Cudkovic ME, Brown MV, et al. Biochemical alterations associated with ALS. *Amyotroph Lateral Scler* 2012;13:110–118.
27. Lawton KA, Brown MV, Alexander D, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. *Amyotroph Lateral Scler Frontotemporal Degener* 2014;15:362–370.
28. Smith QR, Momma S, Aoyagi M, Rapoport SI. Kinetics of neutral amino acid transport across the blood-brain barrier. *J Neurochem* 1987;49:1651–1658.
29. Kanamori K, Ross BD, Kondrat RW. Rate of glutamate synthesis from leucine in rat brain measured in vivo by 15N NMR. *J Neurochem* 1998;70:1304–1315.
30. Van Damme P, Dewil M, Robberecht W, Van Den Bosch L. Excitotoxicity and amyotrophic lateral sclerosis. *Neurodegener Dis* 2005;2:147–159.
31. Contruscieri V, Paradisi S, Matteucci A, Malchiodi-Albedi F. Branched-chain amino acids induce neurotoxicity in rat cortical cultures. *Neurotox Res* 2010;17:392–398.
32. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. *Lancet* 2011;377:942–955.
33. Stickler DE, Royer JA, Hardin JW. Accuracy and usefulness of ICD-10 death certificate coding for the identification of patients with ALS: results from the South Carolina ALS Surveillance Pilot Project. *Amyotroph Lateral Scler* 2012;13:69–73.
34. Kioumourtoglou MA, Seals RM, Himmerslev L, Gredal O, Hansen J, Weisskopf MG. Comparison of diagnoses of amyotrophic lateral sclerosis by use of death certificates and hospital discharge data in the Danish population. *Amyotroph Lateral Scler Frontotemporal Degener* 2015;16:224–229.
35. Townsend MK, Clish CB, Kraft P, et al. Reproducibility of metabolomic profiles among men and women in 2 large cohort studies. *Clin Chem* 2013;59:1657–1667.



# Neurology®

## Prediagnostic plasma branched-chain amino acids and the risk of amyotrophic lateral sclerosis

Kjetil Bjornevik, Éilis J. O'Reilly, James D. Berry, et al.  
*Neurology* 2019;92:e2081-e2088 Published Online before print November 14, 2018  
DOI 10.1212/WNL.0000000000006669

**This information is current as of November 14, 2018**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/92/18/e2081.full">http://n.neurology.org/content/92/18/e2081.full</a>
<b>References</b>	This article cites 34 articles, 9 of which you can access for free at: <a href="http://n.neurology.org/content/92/18/e2081.full#ref-list-1">http://n.neurology.org/content/92/18/e2081.full#ref-list-1</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>All CBMRT/Null Hypothesis</b> <a href="http://n.neurology.org/cgi/collection/all_cbmrt_null_hypothesis">http://n.neurology.org/cgi/collection/all_cbmrt_null_hypothesis</a> <b>Amyotrophic lateral sclerosis</b> <a href="http://n.neurology.org/cgi/collection/amyotrophic_lateral_sclerosis">http://n.neurology.org/cgi/collection/amyotrophic_lateral_sclerosis</a> <b>Cohort studies</b> <a href="http://n.neurology.org/cgi/collection/cohort_studies">http://n.neurology.org/cgi/collection/cohort_studies</a> <b>Risk factors in epidemiology</b> <a href="http://n.neurology.org/cgi/collection/risk_factors_in_epidemiology">http://n.neurology.org/cgi/collection/risk_factors_in_epidemiology</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2018 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

